已收盘 11-20 16:00:00 美东时间
+0.460
+1.00%
Sanofi weighs potential Insmed acquisition to offset Dupixent patent loss, prompting analysts to weigh respiratory synergy against deal cost and capacity.
今天 01:14
Insmed (INSM) stock surges over 18% after reports that French pharma giant Sanofi (SNY) is exploring a potential takeover.
11-20 02:57
https://www.bloomberg.com/news/articles/2026-11-19/sanofi-weighs-takeover-of-us-drugmaker-insmed
11-19 23:17
Agreement paves the way for newly diagnosed, transplant-ineligible patients fighting multiple myeloma to access first-line treatment Sarclisa® through provincial and territorial cancer treatment formulary listings.
11-16 22:16
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across
07-10 20:55
Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth up to $2.1 billion.
07-08 22:14
EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany and France.
06-29 23:44
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.
06-24 00:21